Related Experiment Video
Updated: Dec 21, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
QT Prolongation and Oncology Drug Development
Michael G Fradley1, Javid Moslehi2
1Division of Cardiovascular Medicine, Morsani College of Medicine, University of South Florida, 2 Tampa General Circle, Tampa, FL 33606, USA.
Many drugs affect cardiac ion channels, potentially prolonging the QT interval and causing dangerous arrhythmias. Accurate QT interval measurement is crucial in drug development, though challenging, as significant prolongation can halt drug approval.
Area of Science:
- Pharmacology
- Cardiology
- Drug Development
Background:
- Pharmaceutical agents can interact with cardiac ion channels.
- This interaction may lead to abnormal ventricular repolarization and QT interval prolongation.
- QT interval prolongation can, in rare cases, cause life-threatening torsades de pointes arrhythmia.
Purpose of the Study:
- To highlight the significance of QT interval monitoring in pharmaceutical development.
- To underscore the challenges and limitations of QT interval measurement as a predictor of arrhythmia.
- To emphasize the impact of QT interval prolongation on drug approval.
Main Methods:
- Review of existing literature on drug-induced QT interval prolongation.
- Analysis of the relationship between QT interval changes and torsades de pointes.
- Discussion of regulatory considerations for QT interval monitoring in drug development.
Main Results:
- Drug interactions with cardiac ion channels are a known cause of QT prolongation.
- Accurate QT interval measurement is difficult and an imperfect predictor of torsades de pointes.
- Significant QT prolongation is a critical factor that can prevent drug approval.
Conclusions:
- QT interval monitoring remains essential in pharmaceutical research despite measurement challenges.
- Understanding the risk of drug-induced QT prolongation is vital for patient safety and drug development success.
- Regulatory agencies closely scrutinize QT interval data during drug evaluation.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013